BIOPHARMA
By
Can AstraZeneca’s Imfinzi Redefine Gastric Cancer Treatment With FDA Priority Review Backing?
Key Highlights A New Chapter for Immunotherapy in Early-Stage GI CancersAstraZeneca’s Imfinzi is poised to become the first…
Could GSK and Hengrui’s $12B Alliance Set a New Standard in China-Originated Drug Collaborations?
Key Highlights GSK Bets Big on Hengrui: A $12B Strategic Play Anchored in Respiratory InnovationIn a high-stakes bet…
Will Sanofi’s AI Ethics Revolution Trigger a $100 Billion Shift in Biopharma and Medtech? How the Company’s Transparency Drive is Reshaping Global Healthcare
Key Highlights: AI Ethics at Scale: Sanofi Sets Global Leadership StandardSanofi’s establishment of a dedicated AI Ethical Review…
Can IGC Pharma’s New AI Models Change Alzheimer’s Diagnosis and Drug Discovery for Millions?
New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings Key…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
